Homepage | RMD Open | A leading rheumatology journal from …
网页RMD Open. RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies ...
Authors | RMD Open | A leading rheumatology journal from …
网页RMD Open is an open access journal and levies an Article Processing Charge (APC) of 2,163 GBP (exclusive of VAT for UK and EU authors). The APC for Letters is 1,082 GBP. There are no submission, colour or page charges. There is a 25% discount for articles where the corresponding author has reviewed for RMD Open within the previous 12 months. A 50% discount on the standard APC will apply to ...
Safety profile of upadacitinib over 15 000 patient-years across ...
网页Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD). Methods Safety data from clinical trials of upadacitinib 15 mg and upadacitinib 30 mg (AD only) for treating RA, PsA, AS and AD as of 30 June 2021 were analysed; some RA and PsA studies included adalimumab and ...
About | RMD Open | A leading rheumatology journal from EULAR …
网页RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to ...
Anifrolumab: the new frontier in the treatment of genetic ...
网页4 天之前 · The idea of a detrimental effect of IFN-I emerged in the 1970s when high levels of IFN-I were found in the blood of patients with systemic lupus erythematosus (SLE) compared with healthy individuals.1 In the same decade, Gresser et al provided evidence of the toxic effect of IFN-I in mouse and rat models.2 3 These observations were further supported by the development of SLE following IFN ...
Long versus short-term opioid therapy for fibromyalgia syndrome …
网页4 天之前 · Methods Retrospective cohort study combing several population-wide databases covering a population of five million inhabitants, including all adults who received an initial opioid prescription from 2014 to 2018 specifically prescribed for FMS. We examined the occurrence of depression, sleep disorders or suicidal ideation outcomes in patients with an initial long-term opioid prescription (>90 ...
Phase 3, long-term, open-label extension period of safety and …
网页Objectives To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in China. Methods In this phase 3, open-label extension period, eligible completers of study BEL113750 ([NCT01345253][1]) received intravenous belimumab 10 mg/kg monthly for ≤6 years. The primary endpoint was safety. Secondary endpoints included the SLE Responder Index ...
Efficacy and safety of intra-articular therapies in rheumatic and ...
网页Objective To summarise the evidence on intra-articular therapies (IAT) to inform the 2020 EULAR recommendations. Methods An overview of systematic reviews (SR) including randomised-controlled trials (RCTs) of IAT in adults with arthropathies was performed up to July 2020. Pain, function, and frequency of adverse events were the main efficacy and safety outcomes, respectively.
Immune responses to mRNA vaccines against SARS-CoV-2 in
网页Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated extraordinary efficacy across all ages. Immunosuppressed patients were excluded from phase III trials with SARS-CoV-2 mRNA vaccines. Aims To fully characterise B-cell and T-cell immune responses ...
Biologicals in rheumatoid arthritis: current and future - RMD Open
网页The aim of the review is to highlight the current knowledge about established and new biologicals and to summarise recent advances by focusing on comparative efficacy, safety and possible discontinuation of treatment in patients with rheumatoid arthritis (RA). Up to now, comparative analyses showed only minor differences with respect to efficacy and safety among the established biologicals.